OncoNano Medicine Inc (OncoNano) is biotechnology company that develops pH-activated compounds that digitalize and exploit the variability of pH in disease. The company pipeline includes ON501. The company utilizes pH variability, a biomarker to detect and treat diseased tissue. OncoNano’s ON-BOARD micelle platform carries a wide variety of payloads for systemic administration to the tumor microenvironment and OMNI platform deliver therapeutic payloads and directly activates a ubiquitous immune signaling molecule for cancer immunotherapy. It develops products in the therapeutic areas of cancer, alzheimer’s and metabolic disorders. OncoNano is headquartered in Southlake, Texas, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company OncoNano Medicine Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
OncoNano Medicine Inc Company Overview
OncoNano Medicine Inc Company Snapshot
OncoNano Medicine Inc Pipeline Products and Ongoing Clinical Trials Overview
OncoNano Medicine Inc – Pipeline Analysis Overview
OncoNano Medicine Inc - Key Facts
OncoNano Medicine Inc - Major Products and Services
OncoNano Medicine Inc Pipeline Products by Development Stage
OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
OncoNano Medicine Inc - Locations And Subsidiaries
Head Office
Recent Developments
OncoNano Medicine Inc, Recent Developments
Nov 06, 2023: OncoNano Medicine Announces Promotion of Kartik Krishnan, MD, PhD, to President and Head of Research & Development
Aug 25, 2023: AHN Cancer Institute Leads Clinical Trial of Fluorescent Agent That “Lights Up” Previously Undetectable Cancer Cells to Guide Surgical Resection
May 31, 2023: OncoNano Medicine positivec final results from phase 2 trial of Pegsitacianine in Podium presentation at 2023 ASCO Annual Meeting
Apr 27, 2023: OncoNano Medicine announces oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Mar 27, 2023: OncoNano Medicine presents data from phase 2 pegsitacianine study at Society of Surgical Oncology (SSO) 2023 International Congress on Surgical Cancer Care
Jan 04, 2023: OncoNano Medicine’s Pegsitacianine granted breakthrough therapy designation for real-time surgical imaging by the Food and Drug Administration
Nov 14, 2022: OncoNano Medicine Announces New Preclinical Data for ON-BOARD Platform for Delivery of Bispecific T Cell Engagers and a Therapeutic Cytokine at the Society for Immunotherapy of Cancer Annual Meeting
Sep 29, 2022: OncoNano Medicine announces positive phase 2 data for pegsitacianine as an adjunct to cytoreductive surgery of peritoneal carcinomatosis
Sep 14, 2022: OncoNano Medicine announces oral presentation of phase 2 study data at the World Molecular Imaging Congress 2022
Mar 10, 2022: OncoNano Medicine to present at the American Association for Cancer Research (AACR) Annual Meeting 2022
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Table 1: OncoNano Medicine Inc Pipeline Products and Ongoing Clinical Trials Overview
Table 2: OncoNano Medicine Inc Pipeline Products by Equipment Type
Table 3: OncoNano Medicine Inc Pipeline Products by Indication
Table 4: OncoNano Medicine Inc, Key Facts
Table 5: OncoNano Medicine Inc, Major Products and Services
Table 6: OncoNano Medicine Inc Number of Pipeline Products by Development Stage
Table 7: OncoNano Medicine Inc Pipeline Products Summary by Development Stage
Table 8: OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status
Table 9: OncoNano Medicine Inc Ongoing Clinical Trials Summary
Table 10: ONM-100 - Product Status
Table 11: ONM-100 - Product Description
Table 12: ONM-300 - Product Status
Table 13: ONM-300 - Product Description
Table 14: Pegsitacianine Intraoperative Imaging Agent - Product Status
Table 16: Pegsitacianine Intraoperative Imaging Agent - A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Table 17: OncoNano Medicine Inc, Key Employees
Table 18: Glossary
List of Figures
Figure 1: OncoNano Medicine Inc Pipeline Products by Equipment Type
Figure 2: OncoNano Medicine Inc Pipeline Products by Development Stage
Figure 3: OncoNano Medicine Inc Ongoing Clinical Trials by Trial Status